Teva Pharmaceutical Industries Ltd.

Director's Dealing • Mar 8, 2024

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response ... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Daniell Richard	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 10% Owner Director
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 03/05/2024	Officer (give title below) Other (specify below) Exec. VP, European Commercial
(Street) Tel Aviv, L3 6944020 (City) (State) (Zip)	4. If Amendment, Date Original Filed (Month/Day/Year)	(6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

i.Title of Security	2. Transaction	2A. Deemed	3. Transaction		4. Securities Acquired			5. Amount of Securities Beneficially		7. Nature
(Instr. 3)	Date	Execution Date, if Code			(A) or Disposed of (D)			Owned Following Reported		Ownership of Indirect
	(Month/Day/Year) any		(Instr. 8)		(Instr. 3, 4 and 5)			Transaction(s)	Form:	Beneficial
		י (Month/Day/Year)						(Instr. 3 and 4)		Direct (D) Ownership
						(A)			or Indirect (Instr. 4)
						Or			(1)
			Code		Amount	(D)	Price		(Instr. 4)
Ordinary Shares (1)	03/05/2024		M		22,576	A	(2)	92,346	D

Ordinary Shares (1)	03/05/2024	(3)	22,576 D		13.5154 (4)	69,770	D
Ordinary Shares (1)	03/05/2024	M	55,226 A		(2)	124,996	D
Ordinary Shares (1)	03/05/2024	S(3)	26,053 (5)	D	13.5154 (4)	98,943	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	Conversion Date or Exercise Price of Derivative Security	3. Transaction (Month/Day/Year) any	3A. Deemed Execution Date, if Transaction of Derivative and Expiration Date (Month/Day/Year) (Instr. 8)	4 Code		5. Number Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Security (Instr. 5)	8. Price of 9. Number of Derivative Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Form of Derivative Security: Direct (D) or Indirect (1) (Instr. 4)	11. Nature Ownership of Indirect Beneficial Ownership (Instr. 4)
				Code		(A)	(D)	Date Exercisable Date	Expiration	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2024		M			22,576	(6)	(6)	Ordinary Shares (1)	22,576	\$ 0	22,576	D
Restricted Share Units	(2)	03/05/2024		M			55,226	(7)	(7)	Ordinary Shares (1)	55,226	\$ 0	0	D

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 2 Each restricted share unitingent right to receive, at settlement, one ordinary share or at the option of the Human Resources and Committer, the cash vale of one ordinary share.
• 1. The transaction reported in this Form 4 was effected pursuant to a Rule 1065-1 trading plan adopted by the reporting person on November 13, 2023.
• 1. The price reported in Column 4 is a weighted and in multiple transactions at prices ranging from \$1.41 to \$1.6 , including , The reporting person undercakes to provide, upon request by the issuer, or any security holder of the issuer, fill information regarding the number of shares sold at each separate price.
• 1. Represents the number of stares required to be sold by the reason to over tax withbolding obligations in comecion with the vesting of the restricted share units listed in II.
• 1. Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2023, March 5, 2025.
• 1. Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 03/07/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of inthis form are not required to respond unless the form displays a currently valid OMB Number.